Quick Takeaways
- SUVRETTA CAPITAL MANAGEMENT, LLC filed SCHEDULE 13G for Lexeo Therapeutics, Inc. Common stock, par value $0.0001 (LXEO).
- Disclosed ownership: 7.7%.
- Date of event: 06 Apr 2026.
SUVRETTA CAPITAL MANAGEMENT, LLC - 06 Apr 2026 SCHEDULE 13G Report for Lexeo Therapeutics, Inc. Common stock, par value $0.0001 (LXEO)
- Filing Manager
- SUVRETTA CAPITAL MANAGEMENT, LLC
- Reporting Manager
- SUVRETTA CAPITAL MANAGEMENT, LLC
- Symbol
- LXEO
- Shares outstanding
- 73,698,416 shares
- Disclosed Ownership
- 5,674,778 shares
- Ownership
- 7.7%
- Form type
- SCHEDULE 13G
- Filing time
- 13 Apr 2026, 17:03:58 UTC
- Date of event
- 06 Apr 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"SUVRETTA CAPITAL MANAGEMENT, LLC disclosed 7.7% ownership in Lexeo Therapeutics, Inc. Common stock, par value $0.0001 (LXEO) on 06 Apr 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Apr 2026, 17:03.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% | 5,674,778 | 0 | 5,674,778 | By: /s/ Andrew Nathanson | Andrew Nathanson, General Counsel and Chief Compliance Officer | |
| Averill Master Fund, Ltd. | 6.5% | 4,827,730 | 0 | 4,827,730 | By: /s/ Andrew Nathanson | Andrew Nathanson, Authorized Signatory | |
| AARON COWEN | 7.7% | 5,674,778 | 0 | 5,674,778 | By: /s/ Aaron Cowen | Aaron Cowen |